A detailed history of Prelude Capital Management, LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 21,000 shares of AGIO stock, worth $723,660. This represents 0.06% of its overall portfolio holdings.

Number of Shares
21,000
Previous 21,000 -0.0%
Holding current value
$723,660
Previous $933,000 -0.0%
% of portfolio
0.06%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$41.19 - $49.72 $864,990 - $1.04 Million
21,000 New
21,000 $933,000
Q1 2024

May 15, 2024

BUY
$21.32 - $34.81 $320,993 - $524,099
15,056 New
15,056 $440,000
Q4 2020

Feb 16, 2021

SELL
$33.21 - $46.54 $42,542 - $59,617
-1,281 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$33.87 - $55.93 $94,971 - $156,827
-2,804 Reduced 68.64%
1,281 $45,000
Q2 2020

Aug 14, 2020

BUY
$34.45 - $53.48 $140,728 - $218,465
4,085 New
4,085 $218,000
Q2 2019

Aug 14, 2019

SELL
$46.17 - $68.1 $6,463 - $9,534
-140 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$45.92 - $67.67 $6,428 - $9,473
140 New
140 $9,000
Q4 2018

Feb 14, 2019

SELL
$42.73 - $76.53 $286,333 - $512,827
-6,701 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$71.67 - $91.95 $100,338 - $128,730
1,400 Added 26.41%
6,701 $517,000
Q2 2018

Aug 14, 2018

BUY
$73.22 - $99.55 $377,229 - $512,881
5,152 Added 3457.72%
5,301 $447,000
Q1 2018

May 15, 2018

BUY
$59.83 - $86.53 $8,914 - $12,892
149 New
149 $12,000
Q4 2017

Feb 14, 2018

SELL
$52.12 - $72.33 $219,685 - $304,870
-4,215 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$54.89 - $67.12 $231,361 - $282,910
4,215
4,215 $281,000

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $1.89B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.